Estudos Randomizados
Estudo randomizado | Segurança e eficácia da terceira dose de vacina da Pfizer contra Covid-19 durante a onda Delta.
25 Mar, 2022 | 14:56hSafety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine – New England Journal of Medicine
Comentário no Twitter
A third dose of the BNT162b2 vaccine administered a median of 10.8 months after the second dose provided 95.3% efficacy against Covid-19 as compared with two doses. #COVID19 #IDTwitter https://t.co/IeHOgVhU8a pic.twitter.com/wValXSdyHX
— NEJM (@NEJM) March 23, 2022
[Comunicado de imprensa – ainda não publicado] Estudo randomizado | Abordagem minimamente invasiva para histerectomia no câncer de colo do útero está associada à pior sobrevida livre de doença do que a cirurgia aberta.
25 Mar, 2022 | 14:49hEstudo randomizado | Efeito de um programa de atividade física sobre o declínio da mobilidade funcional em idosos.
23 Mar, 2022 | 12:05hComunicado de imprensa: Landmark study demonstrates long-term positive impacts and cost effectiveness of tailored group exercise for over-65s with mobility limitations
Comentário convidado: Considerations for maintaining functional mobility in older populations – The Lancet Public Health
Estudo randomizado | Levotiroxina não é benéfica para mulheres eutireóideas com anticorpo positivo para peroxidase tireóidea e perda gestacional recorrente.
23 Mar, 2022 | 11:39hLevothyroxine in euthyroid thyroid peroxidase antibody positive women with recurrent pregnancy loss (T4LIFE trial): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Diabetes & Endocrinology (link para o resumo – $ para o texto completo)
Comentário: Levothyroxine No Boon for Birth Rates in Women With Possible Thyroid Disorder – MedPage Today (necessário cadastro gratuito)
Estudo randomizado de fase 2 | Terapia celular derivada de cardiosfera intravenosa repetida na distrofia muscular de Duchenne em estágio tardio.
23 Mar, 2022 | 11:25h
Comentário no Twitter
In patients with late-stage Duchenne muscular dystrophy, CAP-1002 cell therapy appears safe & effective in reducing deterioration of upper limb & cardiac function, trial suggests. Longer-term extension studies needed.
Explore full findings: https://t.co/bCLtsbuJH3 pic.twitter.com/h7vareAMC7
— The Lancet (@TheLancet) March 21, 2022
Estudo randomizado | Eficácia e aceitação de terapias dietéticas na síndrome do intestino irritável sem constipação: um estudo randomizado comparando aconselhamento dietético tradicional, dietas de baixo FODMAP e dietas sem glúten.
22 Mar, 2022 | 11:46hComentário: Traditional Dietary Advice Optimal as an Irritable Bowel Syndrome Therapy – HCPLivre
Conteúdos relacionados:
10 mistakes in dietary management of irritable bowel syndrome and how to avoid them.
Supplement: Irritable bowel syndrome and related conditions.
RCT: FODMAPs, but not gluten, elicit modest symptoms of irritable bowel syndrome.
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Guidelines for the treatment of irritable bowel syndrome
ACG Clinical Guideline: Management of irritable bowel syndrome
M-A: Efficacy of a low-FODMAP diet in adult irritable bowel syndrome
Estudo randomizado | Modalidade de exames de imagem (TC vs. RM) e frequência (7 exames em 60 meses vs. 3 exames em 36 meses) na vigilância do seminoma testicular maligno estágio I.
22 Mar, 2022 | 11:38hImaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST) – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)
Estudo randomizado | Melhora sintomática precoce após terapia com ustequinumabe em pacientes com colite ulcerativa.
22 Mar, 2022 | 11:26hEarly symptomatic improvement after ustekinumab therapy in patients with ulcerative colitis: 16-week data from the UNIFI trial – Clinical Gastroenterology and Hepatology (link para o resumo – $ para o texto completo)
Estudo randomizado | Poractante alfa nebulizado em bebês prematuros com síndrome da angústia respiratória.
22 Mar, 2022 | 11:25hComentário: Should we give up on nebulised surfactant? – Neonatal Research
Comentário no Twitter
The CURONEB RCT by Dani et al. in @JPediatr stopped early, but showed that nebulised poractant alfa is safe but does not reduce respiratory failure within 72 hours in 28-33 weekers https://t.co/gW57rPTd4f #FOAMneo #EBNEOalerts #neoEBM #neotwitter pic.twitter.com/G5Cii33fRD
— Evidence-Based Neo (@EBNEO) March 8, 2022
Estudo randomizado | Suplementação de flavonóis de cacau mostrou-se promissora na prevenção de eventos cardiovasculares.
21 Mar, 2022 | 16:29h
Comentário no Twitter (fio – clique para saber mais)
In @AJCNutrition: @HowardSesso, Dr. JoAnn Manson of @BWHDPM @BrighamWomens & colleagues report the main findings of the first ever randomized trial of a cocoa flavanol supplement on cardiovascular disease endpointshttps://t.co/0F5v8WqzdM and https://t.co/vA3wwT0Amw (1 of 5) pic.twitter.com/X08hiNUCzK
— BrighamResearch (@BrighamResearch) March 16, 2022


